Funding the New Biologics – What Can We Learn from Infliximab? The CCOHTA Report: A Gastroenterologist’s Viewpoint
The treatment of severe Crohn’s disease is difficult, and approximately 20% of patients do not respond to conventional therapy, including corticosteroids and immunosuppressives. Infliximab is one of the only treatments of proven efficacy in this group. Awareness of its benefits and risks is incomple...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2002-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2002/463015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|